Prevalence of Cerebral Microhemorrhages and Cortical Superficial Siderosis in APOE4/4 Homozygotes with Early Alzheimer’s disease: Baseline Findings from Phase 3 Trial of Oral ALZ‐801 in APOE4/4 Homozygotes (APOLLOE4)
Susan Abushakra(Framingham State University), Martin Tolar(Alzheimer's Association), Anton P. Porsteinsson(University of Rochester), Joyce Suhy(BioClinica (United States)), David Watson(Alzheimer’s Disease Neuroimaging Initiative), John A. Hey(Framingham State University), Rosalind McLaine(Framingham State University), Patrick Kesslak, Aidan Power, Earvin Liang, Jerome Barakos(Sutter Health), Emer MacSweeney(Cambridge Cognition (United Kingdom))
Cited by 0
Related Papers
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
|New England Journal of Medicine|2014|2k
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
|Neurology|2009|741
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
|The Lancet Neurology|2010|696